



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

25 March 2015

**CERTIFICATION**

This is to certify the provisional exemption for one year, effective upon receipt of this certificate, of the following medicine:

Medicine: **Deferasirox 125 mg and 250 mg dispersible tablet**

Indication: (1) For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over).  
(2) For the treatment of chronic iron overload in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.

The product shall only be utilized by the requesting party – Philippine General Hospital, and the concerned proponent shall provide to the Formulary Executive Council (FEC) through the National Center for Pharmaceutical Access and Management (NCPAM) the following: (1) local safety profile; (2) surveillance report on adverse effects; and (3) impact study/outcomes of patients using the product. These shall be submitted after expiration of the validity.

For compliance and strict implementation.

  
ANNA MELISSA S. GUERRERO, MD, MPH (HTA)

Division Chief  
Pharmaceutical Division  
Office for Health Regulation